Neuroendocrine Tumor A021602

Study #A021602

Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Prior Therapy

Back To Clinical Trials NCI Database Entry